Hyperhemolytic Syndrome Complicating a Delayed Hemolytic Transfusion Reaction due to anti-P1 Alloimmunization, in a Pregnant Woman with HbO-Arab/β-Thalassemia

Hyperhemolytic Syndrome or Hyperhemolytic Transfusion Reaction (HHTR), a life-threatening subset of Delayed Hemolytic Transfusion Reaction (DHTR) is characterized by destruction of both transfused and autologous erythrocytes evidenced by a fall in post transfusion hemoglobin below the pre-transfusio...

Full description

Saved in:
Bibliographic Details
Published inMediterranean journal of hematology and infectious diseases Vol. 8; no. 1; pp. e2016053 - e201653
Main Authors Bezirgiannidou, Zoe, Christoforidou, Anna, Kontekaki, Eftychia, Anastasiadis, Athanasios G, Papamichos, Spyros I, Menexidou, Helen, Margaritis, Dimitrios, Martinis, Georges, Mantadakis, Elpis
Format Journal Article
LanguageEnglish
Published Italy Mattioli 1885 SpA 18.10.2016
Università Cattolica del Sacro Cuore
Mattioli1885
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hyperhemolytic Syndrome or Hyperhemolytic Transfusion Reaction (HHTR), a life-threatening subset of Delayed Hemolytic Transfusion Reaction (DHTR) is characterized by destruction of both transfused and autologous erythrocytes evidenced by a fall in post transfusion hemoglobin below the pre-transfusion level. We describe a case of DHTR due to anti-P1 alloimmunization manifesting with hyperhemolysis in a 30-year-old Greek Pomak woman with thalassemia intermedia (HbO-Arab/β-thalassemia), during the11 week of her first gestation. She was successfully managed with avoidance of further transfusions and administration of IVIG and corticosteroids. A high index of suspicion for HHTR is of vital importance among clinicians especially since optimal methods for its prevention and treatment remain yet to be defined. Early recognition of HHTR leading to prompt cessation of additional transfusions and initiation of immunosuppressive treatment can be life-saving, especially in clinical settings where limited therapeutic options are available, such as in pregnancy.
ISSN:2035-3006
2035-3006
DOI:10.4084/MJHID.2016.053